48 related articles for article (PubMed ID: 26064972)
1. Identification of a common variant with potential pleiotropic effect on risk of inflammatory bowel disease and colorectal cancer.
Khalili H; Gong J; Brenner H; Austin TR; Hutter CM; Baba Y; Baron JA; Berndt SI; Bézieau S; Caan B; Campbell PT; Chang-Claude J; Chanock SJ; Chen C; Hsu L; Jiao S; Conti DV; Duggan D; Fuchs CS; Gala M; Gallinger S; Haile RW; Harrison TA; Hayes R; Hazra A; Henderson B; Haiman C; Hoffmeister M; Hopper JL; Jenkins MA; Kolonel LN; Küry S; LaCroix A; Marchand LL; Lemire M; Lindor NM; Ma J; Manson JE; Morikawa T; Nan H; Ng K; Newcomb PA; Nishihara R; Potter JD; Qu C; Schoen RE; Schumacher FR; Seminara D; Taverna D; Thibodeau S; Wactawski-Wende J; White E; Wu K; Zanke BW; Casey G; Hudson TJ; Kraft P; Peters U; Slattery ML; Ogino S; Chan AT;
Carcinogenesis; 2015 Sep; 36(9):999-1007. PubMed ID: 26071399
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide association study of colorectal cancer identifies six new susceptibility loci.
Schumacher FR; Schmit SL; Jiao S; Edlund CK; Wang H; Zhang B; Hsu L; Huang SC; Fischer CP; Harju JF; Idos GE; Lejbkowicz F; Manion FJ; McDonnell K; McNeil CE; Melas M; Rennert HS; Shi W; Thomas DC; Van Den Berg DJ; Hutter CM; Aragaki AK; Butterbach K; Caan BJ; Carlson CS; Chanock SJ; Curtis KR; Fuchs CS; Gala M; Giovannucci EL; Gogarten SM; Hayes RB; Henderson B; Hunter DJ; Jackson RD; Kolonel LN; Kooperberg C; Küry S; LaCroix A; Laurie CC; Laurie CA; Lemire M; Levine D; Ma J; Makar KW; Qu C; Taverna D; Ulrich CM; Wu K; Kono S; West DW; Berndt SI; Bezieau S; Brenner H; Campbell PT; Chan AT; Chang-Claude J; Coetzee GA; Conti DV; Duggan D; Figueiredo JC; Fortini BK; Gallinger SJ; Gauderman WJ; Giles G; Green R; Haile R; Harrison TA; Hoffmeister M; Hopper JL; Hudson TJ; Jacobs E; Iwasaki M; Jee SH; Jenkins M; Jia WH; Joshi A; Li L; Lindor NM; Matsuo K; Moreno V; Mukherjee B; Newcomb PA; Potter JD; Raskin L; Rennert G; Rosse S; Severi G; Schoen RE; Seminara D; Shu XO; Slattery ML; Tsugane S; White E; Xiang YB; Zanke BW; Zheng W; Le Marchand L; Casey G; Gruber SB; Peters U
Nat Commun; 2015 Jul; 6():7138. PubMed ID: 26151821
[TBL] [Abstract][Full Text] [Related]
3. Genetic Variation in DEAD-Box Helicase 20 as a Putative Marker of Recurrence in Propensity-Matched Colon Cancer Patients.
Hobani YH; Almars AI; Alelwani W; Toraih EA; Nemr NA; Shaalan AAM; Fawzy MS; Attallah SM
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011315
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive analysis of SNPs and CNVs identifies novel markers associated with disease outcomes in colorectal cancer.
Yu Y; Werdyani S; Carey M; Parfrey P; Yilmaz YE; Savas S
Mol Oncol; 2021 Dec; 15(12):3329-3347. PubMed ID: 34309201
[TBL] [Abstract][Full Text] [Related]
5. Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival.
Faluyi OO; Eng L; Qiu X; Che J; Zhang Q; Cheng D; Ying N; Tse A; Kuang Q; Dodbiba L; Renouf DJ; Marsh S; Savas S; Mackay HJ; Knox JJ; Darling GE; Wong RK; Xu W; Azad AK; Liu G
Cancer Med; 2017 Feb; 6(2):361-373. PubMed ID: 28074552
[TBL] [Abstract][Full Text] [Related]
6. A Survival Association Study of 102 Polymorphisms Previously Associated with Survival Outcomes in Colorectal Cancer.
Savas S; Xu J; Werdyani S; Shestopaloff K; Dicks E; Green J; Parfrey P; Green R; Xu W
Biomed Res Int; 2015; 2015():968743. PubMed ID: 26064972
[TBL] [Abstract][Full Text] [Related]
7. Examining the polymorphisms in the hypoxia pathway genes in relation to outcome in colorectal cancer.
Haja Mohideen AM; Hyde A; Squires J; Wang J; Dicks E; Younghusband B; Parfrey P; Green R; Savas S
PLoS One; 2014; 9(11):e113513. PubMed ID: 25405996
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial DNA polymorphisms, its copy number change and outcome in colorectal cancer.
Mohideen AM; Dicks E; Parfrey P; Green R; Savas S
BMC Res Notes; 2015 Jun; 8():272. PubMed ID: 26116242
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
Kim JG; Chae YS; Sohn SK; Moon JH; Ryoo HM; Bae SH; Kum Y; Jeon SW; Lim KH; Kang BM; Park IJ; Choi GS; Jun SH
Cancer Chemother Pharmacol; 2009 Oct; 64(5):953-60. PubMed ID: 19219602
[TBL] [Abstract][Full Text] [Related]
10. Colorectal cancer susceptibility loci and influence on survival.
Song N; Kim K; Shin A; Park JW; Chang HJ; Shi J; Cai Q; Kim DY; Zheng W; Oh JH
Genes Chromosomes Cancer; 2018 Dec; 57(12):630-637. PubMed ID: 30350386
[TBL] [Abstract][Full Text] [Related]
11. Association of hypoxia-inducible factor 1-alpha gene polymorphisms and colorectal cancer prognosis.
Szkandera J; Knechtel G; Stotz M; Hofmann G; Langsenlehner U; Krippl P; Langsenlehner T; Dehchamani D; Samonigg H; Renner W; Gerger A
Anticancer Res; 2010 Jun; 30(6):2393-7. PubMed ID: 20651398
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
